Report cover image

Pulmonary Arterial Hypertension (PAH) Market

Publisher Future Market Insights
Published Aug 17, 2023
Length 170 Pages
SKU # FMARI18215310

Description

Pulmonary Arterial Hypertension (PAH) Market Analysis By Drug Class (Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), Phosphodiesterase-5 (PDE-5) Inhibitors, Soluble Guanylate Cyclase (sGC) Stimulators), By Pipeline Analysis (Early-stage Drug Candidates (Phase I & Phase II), Late-stage Drug Candidates (Phase III & Registration Phase)) and Region - Global Market Insights 2023 to 2033


Pulmonary Arterial Hypertension (PAH) Market - Scope of Report

A recent study by Fact.MR on the pulmonary arterial hypertension (pah) market offers a 10-year forecast for 2023 to 2033. The study analyzes crucial trends that are currently determining the growth of the market. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders as well as emerging players associated with offering pulmonary arterial hypertension (pah).

The study also provides the dynamics responsible for influencing the future status of the pulmonary arterial hypertension (pah) market over the forecast period. A detailed assessment of value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report.

A list of prominent companies operating in the pulmonary arterial hypertension (pah) market, along with their product portfolios, key strategies and SWOT analysis, enhances the reliability of this comprehensive research study.

Report Summary

The study offers comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales of pulmonary arterial hypertension (pah) across the globe.

A comprehensive estimate on the market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of pulmonary arterial hypertension (pah) during the forecast period. Price point comparison by region with global average price is also considered in the study.

Analysis on Market Size Evaluation

The market has been analyzed for each segment in terms of value (US$ Mn).

Estimates at global and regional levels for pulmonary arterial hypertension (pah) are available in terms of “US$ Mn” for value. A Y-o-Y growth contrast on prominent market segments, along with market attractiveness evaluation, has been incorporated in the report. Furthermore, absolute dollar opportunity analysis of all the segments adds prominence to the report.

Absolute dollar opportunity plays a crucial role in assessing the level of opportunity that a manufacturer/distributor can look to achieve, along with identifying potential resources, considering the sales and distribution perspective in the global pulmonary arterial hypertension (pah) market.

Inspected Assessment on Regional Segments

Key sections have been elaborated in the report, which have helped deliver projections on regional markets. These chapters include regional macros (political, economic, and business environment outlook), which are expected to have a momentous influence on the growth of the pulmonary arterial hypertension (pah) market during the forecast period.

Country-specific valuation on demand for pulmonary arterial hypertension (pah) has been offered for each region, along with market scope estimates and forecasts, price index, and impact analysis of the dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.

Detailed breakup in terms of value & volume for emerging countries has also been included in the report.

In-depth Analysis on Competition

The report sheds light on leading manufacturers of pulmonary arterial hypertension (pah), along with their detailed profiles. Essential and up-to-date data related to market performers who are principally engaged in offering pulmonary arterial hypertension (pah) has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits report readers to take preemptive steps in advancing their businesses.

Company profiles have been included in the report, which include essentials such as product portfolios and key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting the market status, and predicting the competition level in the pulmonary arterial hypertension (pah) domain.

Table of Contents

170 Pages
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions/Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product modifications /Innovation
4. Key Success Factors
4.1. Strategic Developments
4.2. Key regulations
4.3. Product USPs /Technology
4.4. List of manufacturers and providers
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP outlook
5.1.2. Increasing R&D Expenditure
5.2. Forecast Factors - Relevance & Impact
5.2.1. New product launches
5.2.2. Cost of products
5.2.3. Increasing adoption of Pulmonary Arterial Hypertension (PAH)s
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID19 Crisis Analysis
6.1. Current COVID19 Statistics and Probable Future Impact
6.2. Current GDP Projection and Probable Impact
6.3. Current Economic Projection as compared to 2008 Economic analysis
6.4. COVID19 and Impact Analysis
6.4.1. Revenue By Drug Class
6.4.2. Revenue By Pipeline Analysis
6.4.3. Revenue By Country
6.5. 2020 Market Scenario
6.6. Quarter by Quarter Forecast
6.7. Projected Recovery Quarter
7. Global Market Volume (Units) Analysis 2018-2022 and Forecast, 2023-2033
7.1. Historical Market Volume (Units) Analysis, 2018-2022
7.2. Current and Future Market Volume (Units) Projections, 2023-2033
7.2.1. Y-o-Y Growth Trend Analysis
8. Global Market - Pricing Analysis
8.1. Regional Pricing Analysis By Drug Class
8.2. Pricing Break-up
8.2.1. Manufacturer Level Pricing
8.2.2. Distributor Level Pricing
8.3. Global Average Pricing Analysis Benchmark
9. Global Market Value Analysis 2018-2022 and Forecast, 2023-2033
9.1. Historical Market Value (US$ Mn) Analysis, 2018-2022
9.2. Current and Future Market Value (US$ Mn) Projections, 2023-2033
9.2.1. Y-o-Y Growth Trend Analysis
9.2.2. Absolute $ Opportunity Analysis
10. Global Market Analysis 2018-2022 and Forecast 2023-2033, by Drug Class
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By Products & Services, 2018-2022
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Class, 2023-2033
10.3.1. Prostacyclin & Prostacyclin Analogs
10.3.2. Endothelin Receptor Antagonists (ERAs)
10.3.3. Phosphodiesterase-5 (PDE-5) Inhibitors
10.3.4. Soluble Guanylate Cyclase (sGC) Stimulators
10.4. Market Attractiveness Analysis By Drug Class
11. Global Market Analysis 2018-2022 and Forecast 2023-2033, by Pipeline Analysis
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis By Pipeline Analysis, 2018-2022
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Pipeline Analysis, 2023-2033
11.3.1. Early-stage Drug Candidates (Phase I & Phase II)
11.3.2. Late-stage Drug Candidates (Phase III & Registration Phase)
11.4. Market Attractiveness Analysis By Pipeline Analysis
12. Global Market Analysis 2018-2022 and Forecast 2023-2033, by Region
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Analysis By Region, 2018-2022
12.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2023-2033
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. East Asia
12.3.5. South Asia
12.3.6. Oceania
12.3.7. Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis By Region
13. North America Market Analysis 2018-2022 and Forecast 2023-2033
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033
13.3.1. By Country
13.3.1.1. U.S.
13.3.1.2. Canada
13.3.2. By Drug Class
13.3.3. By Pipeline Analysis
13.4. Market Attractiveness Analysis
13.5. Key Market Participants - Intensity Mapping
13.6. Drivers and Restraints - Impact Analysis
14. Latin America Market Analysis 2018-2022 and Forecast 2023-2033
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033
14.3.1. By Country
14.3.1.1. Brazil
14.3.1.2. Mexico
14.3.1.3. Argentina
14.3.1.4. Rest of Latin America
14.3.2. By Drug Class
14.3.3. By Pipeline Analysis
14.4. Market Attractiveness Analysis
14.5. Key Market Participants - Intensity Mapping
14.6. Drivers and Restraints - Impact Analysis
15. Europe Market Analysis 2018-2022 and Forecast 2023-2033
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033
15.3.1. By Country
15.3.1.1. Germany
15.3.1.2. Italy
15.3.1.3. France
15.3.1.4. U.K.
15.3.1.5. Spain
15.3.1.6. Russia
15.3.1.7. Rest of Europe
15.3.2. By Drug Class
15.3.3. By Pipeline Analysis
15.4. Market Attractiveness Analysis
15.5. Key Market Participants - Intensity Mapping
15.6. Drivers and Restraints - Impact Analysis
16. South Asia Market Analysis 2018-2022 and Forecast 2023-2033
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033
16.3.1. By Country
16.3.1.1. India
16.3.1.2. Thailand
16.3.1.3. Indonesia
16.3.1.4. Malaysia
16.3.1.5. Rest of South Asia
16.3.2. By Drug Class
16.3.3. By Pipeline Analysis
16.4. Market Attractiveness Analysis
16.5. Key Market Participants - Intensity Mapping
16.6. Drivers and Restraints - Impact Analysis
17. East Asia Market Analysis 2018-2022 and Forecast 2023-2033
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033
17.3.1. By Country
17.3.1.1. China
17.3.1.2. Japan
17.3.1.3. South Korea
17.3.1.4. Rest of East Asia
17.3.2. By Drug Class
17.3.3. By Pipeline Analysis
17.4. Market Attractiveness Analysis
17.5. Key Market Participants - Intensity Mapping
17.6. Drivers and Restraints - Impact Analysis
18. Oceania Market Analysis 2018-2022 and Forecast 2023-2033
18.1. Introduction
18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033
18.3.1. By Country
18.3.1.1. Australia
18.3.1.2. New Zealand
18.3.2. By Drug Class
18.3.3. By Pipeline Analysis
18.4. Market Attractiveness Analysis
18.5. Key Market Participants - Intensity Mapping
18.6. Drivers and Restraints - Impact Analysis
19. Middle East and Africa Market Analysis 2018-2022 and Forecast 2023-2033
19.1. Introduction
19.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
19.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033
19.3.1. By Country
19.3.1.1. GCC Countries
19.3.1.2. South Africa
19.3.1.3. Rest of Middle East and Africa
19.3.2. By Drug Class
19.3.3. By Pipeline Analysis
19.4. Market Attractiveness Analysis
19.5. Drivers and Restraints - Impact Analysis
20. Key and Emerging Countries Market Analysis 2018-2022 and Forecast 2023-2033
20.1. Introduction
20.1.1. Market Value Proportion Analysis, By Key Countries
20.1.2. Global Vs. Country Growth Comparison
20.2. U.S. Market Analysis
20.2.1. By Drug Class
20.2.2. By Pipeline Analysis
20.3. Canada Market Analysis
20.3.1. By Drug Class
20.3.2. By Pipeline Analysis
20.4. Mexico Market Analysis
20.4.1. By Drug Class
20.4.2. By Pipeline Analysis
20.5. Brazil Market Analysis
20.5.1. By Drug Class
20.5.2. By Pipeline Analysis
20.6. U.K. Market Analysis
20.6.1. By Drug Class
20.6.2. By Pipeline Analysis
20.7. Germany Market Analysis
20.7.1. By Drug Class
20.7.2. By Pipeline Analysis
20.8. France Market Analysis
20.8.1. By Drug Class
20.8.2. By Pipeline Analysis
20.9. Italy Market Analysis
20.9.1. By Drug Class
20.9.2. By Pipeline Analysis
20.10. Spain Market Analysis
20.10.1. By Drug Class
20.10.2. By Pipeline Analysis
20.11. BENELUX Market Analysis
20.11.1. By Drug Class
20.11.2. By Pipeline Analysis
20.12. Russia Market Analysis
20.12.1. By Drug Class
20.12.2. By Pipeline Analysis
20.13. China Market Analysis
20.13.1. By Drug Class
20.13.2. By Pipeline Analysis
20.14. Japan Market Analysis
20.14.1. By Drug Class
20.14.2. By Pipeline Analysis
20.15. South Korea Market Analysis
20.15.1. By Drug Class
20.15.2. By Pipeline Analysis
20.16. India Market Analysis
20.16.1. By Drug Class
20.16.2. By Pipeline Analysis
20.17. ASEAN Market Analysis
20.17.1. By Drug Class
20.17.2. By Pipeline Analysis
20.18. Australia Market Analysis
20.18.1. By Drug Class
20.18.2. By Pipeline Analysis
20.19. New Zealand Market Analysis
20.19.1. By Drug Class
20.19.2. By Pipeline Analysis
20.20. GCC Countries Market Analysis
20.20.1. By Drug Class
20.20.2. By Pipeline Analysis
20.21. Turkey Market Analysis
20.21.1. By Drug Class
20.21.2. By Pipeline Analysis
20.22. South Africa Market Analysis
20.22.1. By Drug Class
20.22.2. By Pipeline Analysis
21. Market Structure Analysis
21.1. Market Analysis by Tier of Companies
21.2. Market Concentration
21.3. Market Share Analysis of Top Players
21.4. Market Presence Analysis
21.4.1. By Regional footprint of Players
21.4.2. Product foot print by Players
21.4.3. Channel Foot Print by Players
22. Competition Analysis
22.1. Competition Dashboard
22.2. Competition Benchmarking
22.3. Competition Deep dive
22.3.1. Gilead Sciences Inc.
22.3.1.1. Overview
22.3.1.2. Product Portfolio
22.3.1.3. Profitability by Market Segments (Product/Channel/Region)
22.3.1.4. Sales Footprint
22.3.1.5. Strategy Overview
22.3.1.5.1. Marketing Strategy
22.3.1.5.2. Product Strategy
22.3.1.5.3. Channel Strategy
22.3.2. Pfizer, Inc.
22.3.2.1. Overview
22.3.2.2. Product Portfolio
22.3.2.3. Profitability by Market Segments (Product/Channel/Region)
22.3.2.4. Sales Footprint
22.3.2.5. Strategy Overview
22.3.2.5.1. Marketing Strategy
22.3.2.5.2. Product Strategy
22.3.2.5.3. Channel Strategy
22.3.3. GlaxoSmithKline plc
22.3.3.1. Overview
22.3.3.2. Product Portfolio
22.3.3.3. Profitability by Market Segments (Product/Channel/Region)
22.3.3.4. Sales Footprint
22.3.3.5. Strategy Overview
22.3.3.5.1. Marketing Strategy
22.3.3.5.2. Product Strategy
22.3.3.5.3. Channel Strategy
22.3.4. Novartis International AG
22.3.4.1. Overview
22.3.4.2. Product Portfolio
22.3.4.3. Profitability by Market Segments (Product/Channel/Region)
22.3.4.4. Sales Footprint
22.3.4.5. Strategy Overview
22.3.4.5.1. Marketing Strategy
22.3.4.5.2. Product Strategy
22.3.4.5.3. Channel Strategy
22.3.5. Bayer HealthCare
22.3.5.1. Overview
22.3.5.2. Product Portfolio
22.3.5.3. Profitability by Market Segments (Product/Channel/Region)
22.3.5.4. Sales Footprint
22.3.5.5. Strategy Overview
22.3.5.5.1. Marketing Strategy
22.3.5.5.2. Product Strategy
22.3.5.5.3. Channel Strategy
22.3.6. United Therapeutics Corp
22.3.6.1. Overview
22.3.6.2. Product Portfolio
22.3.6.3. Profitability by Market Segments (Product/Channel/Region)
22.3.6.4. Sales Footprint
22.3.6.5. Strategy Overview
22.3.6.5.1. Marketing Strategy
22.3.6.5.2. Product Strategy
22.3.6.5.3. Channel Strategy
23. Assumptions and Acronyms Used
24. Research Methodology

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us